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Abstract: Antimicrobial peptides and structurally related peptoids offer potential for the development
of new antibiotics. However, progress has been hindered by challenges presented by poor in vivo
stability (peptides) or lack of selectivity (peptoids). Herein, we have developed a process to
prepare novel hybrid antibacterial agents that combine both linear peptoids (increased in vivo
stability compared to peptides) and a nisin fragment (lipid II targeting domain). The hybrid
nisin–peptoids prepared were shown to have low micromolar activity (comparable to natural nisin)
against methicillin-resistant Staphylococcus aureus.
Keywords: peptoids; peptoid–peptide hybrid; nisin; antibacterial; alkyne-azide click reactions
1. Introduction
The rapid emergence of antibiotic resistance against commonly used frontline treatments poses
a serious threat to global health and has emphasized the need for novel antimicrobials to be developed.
This urgency is highlighted by increasing academic and industrial interest in the field and the
establishment of enterprises such as the 2015 Ross Fund and the 10 × ‘20 Initiative both of which
encourage the delivery of new antimicrobial drug classes [1,2].
Nisin is a polycyclic peptide produced by several strains of the Gram-positive bacterium
Lactococcus lactis and is an antimicrobial with nanomolar activity against other Gram-positive
bacteria [3,4]. Due to its potent antibacterial activity and negligible toxicity, nisin (Figure 1) is
frequently used as a food preservative and it provides a potential scaffold for the development of novel
antibacterial agents [3,4]. Nisin contains five lanthione bridges which help impart a conformation that
is key to its antibacterial properties [5,6]. In particular the A/B ring system at nisin’s N-terminus has
been shown to bind to lipid II, which is a crucial membrane component used in bacterial cell wall
synthesis. Following lipid II binding, nisin can insert into the bacterial plasma membrane and create
pores that cause cell leakage ultimately leading to cell death [5,7–12].
Given its selective mode of action, nisin provides an excellent starting point for the design of new
antibiotics. However, due to nisin’s peptide-based structure, the clinical development of the full-length
peptide sequence remains challenging. Specifically, the high susceptibility of nisin towards proteolytic
degradation in vivo has presented a major hurdle in its use as a general antibiotic [10,13]. Efforts to
overcome stability issues via the total chemical synthesis or semi-synthesis of nisin analogues with
improved properties have only had limited success [14–16].
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Figure 1. The structure of nisin. Classified as a lantibiotic due to the presence of unusual lanthionine 
rings in its structure, nisin also contains unsaturated amino acids introduced by posttranslational 
modifications: Dhb = dehydrobutyrine, Dha = dehydroalanine and Abu = aminobutyric acid. 
Early studies in the area demonstrated that C-terminally truncated nisin peptides that still contain 
an intact A/B ring system (nisinA/B) can still display low antibacterial activity [17]. The aforementioned 
results, led to numerous truncated nisin peptides being biologically evaluated, including recently 
promising semi-synthetic nisin-lipopeptides [9].  
A strategy that is more commonly being utilized to stabilize peptide-based therapeutics is the 
synthesis of stable peptidomimetics such as peptoids (N-substituted glycines) (Figure 2) [18–20]. 
Peptoids have shown activity as antibacterial [21–28], antifungal [29–31] and antiparasitic [32–35] 
compounds and most importantly they display increased resistance to protease action compared to 
α-peptides [31,36]. In particular, peptoids have demonstrated antibacterial properties against a range 
of clinically relevant Gram negative and Gram positive bacteria, with activities that equal or surpass 
those achieved by many antimicrobial peptides (AMPs) [21–28]. Peptoids are also suspected to 
disrupt cell membranes non-specifically to achieve their antimicrobial effect, with similar modes of 
actions to simple AMPs [21,37]. Given this, peptoids display activity against many drug-resistant 
bacteria. 
 
Figure 2. Representative structure of the backbone of a peptide compared to a peptoid. In peptoids, 
the side chain ‘R’ is moved to the nitrogen of the amide backbone, causing a substantial increase in 
chemical and biological stability. 
Building on from this, we wished to investigate whether we could prepare semi-synthetic nisin 
analogues (e.g., peptide–peptoid hybrids) with comparable antibacterial activity to full-length nisin. 
To this end, we report a new class of peptide–peptoid hybrids that could be used in the development 
of novel antimicrobials. By linking short linear peptoids with the truncated nisinA/B ring fragment, we 
were able to access molecules that have similar antibacterial activity against methicillin-resistant S. 
aureus compared to full-length nisin.  
2. Results and Discussion 
NisinA/B is obtained from the chemo-enzymatic degradation of full-length nisin [38] and this 
fragment can then be modified at the C terminus by addition of an azide functionality [9]. The azide 
provides a convenient handle for ligation to alkynes via a copper-catalyzed click cycloaddition [39]. 
The click reaction between an azide and a terminal alkyne is compatible with a range of conditions, 
tolerates a broad range of chemical functionalities and provides a robust strategy for chemical 
Figure 1. The structure of nisin. Classified as a lantibiotic due to the presence of unusual lanthionine
rings in its structure, nisin also contains unsaturated amino acids introduced by posttranslational
modifications: Dhb = dehydrobutyrine, Dha = dehydroalanine and Abu = aminobutyric acid.
Early studies in the area demonstrated that C-terminally truncated nisin peptides that still contain
an intact A/B ring system (nisinA/B) can still display low antibacterial activity [17]. The aforementioned
results, led to numerous truncated nisin peptides being biologically evaluated, including recently
promising semi-synthetic nisin-lipopeptides [9].
A strategy that is more commonly being utilized to stabilize peptide-based therapeutics is the
synthesis of stable peptidomimetics such as peptoids (N-substituted glycines) (Figure 2) [18–20].
Peptoids have shown activity as antibacterial [21–28], antifungal [29–31] and antiparasitic [32–35]
compounds and most importantly they display increased resistance to protease action compared to
α-peptides [31,36]. In particular, peptoids have demonstrated antibacterial properties against a range
of clinically relevant Gram negative and Gram positive bacteria, with activities that equal or surpass
those achieved by many antimicrobial peptides (AMPs) [21–28]. Peptoids are also suspected to disrupt
cell membranes non-specifically to achieve their antimicrobial effect, with similar modes of actions to
simple AMPs [21,37]. Given this, peptoids display activity against many drug-resistant bacteria.
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Figure 2. Representative structure of the backbone of a peptide co pared to a peptoid. In peptoids,
the side chain ‘R’ is oved to the nitrogen of the a ide backbone, causing a substantial increase in
che ical and biological stability.
Building on from this, we wished to investigate whether we could prepare semi-synthetic nisin
analogues (e.g., peptide–peptoid hybrids) with comparable antibacterial activity to full-length nisin.
To this end, we report a new class of peptide–peptoid hybrids that could be used in the development
of novel antimicrobials. By linking short linear peptoids with the truncated nisinA/B ring fragment,
we were able to access molecules that have similar antibacterial activity against methicillin-resistant
S. aureus compared to full-length nisin.
2. Results and Discussion
NisinA/B is obtained from the chemo-enzymatic degradation of full-length nisin [38] and this
fragment can then be modified at the C terminus by addition of an azide functionality [9]. The azide
provides a convenient handle for ligation to alkynes via a copper-catalyzed click cycloaddition [39].
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The click reaction between an azide and a terminal alkyne is compatible with a range of conditions,
tolerates a broad range of chemical functionalities and provides a robust strategy for chemical ligations.
Furthermore, as an isostere of the amide bond, the triazole formed by click reactions provides
a biocompatible linker that readily associates with biological targets through hydrogen bonding and
dipole interactions [39]. Additionally, the copper (I)-catalyzed click reaction can be performed under
aqueous conditions at room temperature, so is well suited for use with peptide-based reagents [40].
For these reasons, the copper-catalyzed click reaction is ideal for the ligation of azide-functionalzsed
nisin with terminal alkynyl peptoid sequences [41].
Two linear peptoid sequences (peptoid 1a (NaeNspeNspe)4 and 1b
[(NLysNpfbNpfb)(NLysNspeNspe)]2) were chosen as they had shown promising antibacterial
activities with MICs below 2 µM against S. aureus. Peptoids 1a and 1b are both 15
residues in length; i.e., the 12 residue parent sequence followed by two additional Nspe
monomers to lengthen the chain between the last cationic residue and the N terminal Nprp
monomer required for the click reaction. Peptoids 2a NprpNspeNspe(NaeNspeNspe)4 and 2b
NprpNspeNspe[(NLysNpfbNpfb)(NLysNspeNspe)]2 were prepared via the submonomer procedure
for the solid phase synthesis of peptoids, which utilizes successive acylation and displacement cycles
(see Scheme 1). An alkyne tail was added to the sequence using propargylamine (Nprp) under
standard coupling conditions [34,42,43]. Peptoids 2a and 2b were then cleaved from the resin and
purified by RP-HPLC prior to the click reactions being performed.
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bromoacetic acid and DIC in DMF, 20 min, RT; (ii) displacement with primary amine, 1.5 M, RT, 60 
min; (iii) repeated acylation and displacement to complete sequence; (iv) acidic TFA cleavage and 
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Nisin (3) was digested using trypsin and the fragment containing the A/B ring system (4) isolated 
by preparative HPLC. The nisinA/B was then coupled to azidopropylamine and a second RP-HPLC 
purification undertaken to yield the truncated nisin with an azide linker (compound 5 in Scheme 2) [9]. 
Ligation of nisinA/B-azide and the alkyne-tagged peptoids was carried out under microwave 
irradiation using a copper(I)-catalyzed ‘click’ cycloaddition. The active Cu(I) catalyst is generated 
from the Cu(II) salt using sodium ascorbate as a reducing agent and with Tris[(1-benzyl-1H-1,2,3-
triazol-4-yl)methyl]amine (TBTA) as a Cu(I) stabilizing ligand to cleanly afford the expected triazole 
product [39,40,44]. Completion of the click reaction was observed via LC-MS after 20 min microwave 
heating at 80 °C. Coupling times were limited to 20 min to avoid unwanted side reactions (i.e., Dha 
cyclization or lactamization) as previously described [9]. Following a final RP-HPLC purification, the 
expected conjugates (6a and 6b) were obtained in suitable purity for biological testing. Full methods 
and the characterization of 6a and 6b can be found in the Supplementary Materials. 
Scheme 1. Scheme to show the solid-phase, submonomer synthesis of peptoids: (i) acylation using
bromoacetic acid and DIC in DMF, 20 min, RT; (ii) displacement with primary amine, 1.5 M, RT, 60
min; (iii) repeated acylation and displacement to complete sequence; (iv) acidic TFA cleavage and
deprotection of peptoid.
Nisin (3) was digested using trypsin and the fragment containing the A/B ring system (4) isolated
by preparative HPLC. The nisinA/B was then coupled to azidopropylamine and a second RP-HPLC
purification undertaken to yield the truncated nisin with an azide linker (compound 5 in Scheme 2) [9].
Ligation of nisinA/B-azide and the alkyne-tagged peptoids was carried out under microwave
irradiation using a copper(I)-catalyzed ‘click’ cycloaddition. The active Cu(I) catalyst is
generated from the Cu(II) salt using sodium ascorbate as a reducing agent and with
Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) as a Cu(I) stabilizing ligand to cleanly afford
the expected triazole product [39,40,44]. Completion of the click reaction was observed via LC-MS after
20 min microwave heating at 80 ◦C. Coupling times were limited to 20 min to avoid unwanted side
Molecules 2018, 23, 1566 4 of 9
reactions (i.e., Dha cyclization or lactamization) as previously described [9]. Following a final RP-HPLC
purification, the expected conjugates (6a and 6b) were obtained in suitable purity for biological testing.
Full methods and the characterization of 6a and 6b can be found in the Supplementary Materials.
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The antibacterial activity of the nisin–peptoid conjugates 6a and 6b were determined against
methicillin-resistant Staphylococcus aureus USA 300; the predominant strain associated with
community-acquired MRSA infection in the United States [45] (see Table 1). The minimum inhibitory
concentrations (MICs) were calculated and compared to the peptide antibiotic vancomycin 7 and
full-length nisin (3).
Table 1. Biological evaluation of peptide–peptoid conjugates and other fragments for comparison
against methicillin-resistant S. aureus 300. Peptoids and peptide–peptoid hybrids show potent
antibacterial action.
Sequence
MIC (µM) ED50 (µM)
S. aureus (USA300) HaCaT HepG2
7 Vancomycin 1
3 Nisin 5
4 Nisin[1–12] >100
5 Nisin[1–12]-azide 26
1a (NaeNspeNspe)4 2 26 15
1b [(NLysNpfbNpfb)(NLysNspeNspe)]2 2–4 53 18
2a NprpNspeNspe(NaeNspeNspe)4 4 20 12
2b NprpNspeNspe[(NLysNpfbNpfb)(NLysNspeNspe)]2 4–7 15 17
6a Nisin[1–12]-NspeNspe(NaeNspeNspe)4 5–10 24 15
6b Nisin[1–12]-NspeNspe[(NLysNpfbNpfb)(NLysNspeNspe)]2 9–18 22 23
The parent peptoids without an alkyne linker demonstrated excellent activity against the
methicillin-resistant S. aureus, with 1a and 1b displaying MICs of 2 µM and 2–4 µM respectively.
Interestingly, simply functionalizing these peptoid sequences with an N-terminal alkyne reduces their
activity by approximately a factor of 2 (2a, 4 µM and 2b, 4–7 µM). The nisin–peptoid hybrids 6a and
6b also show diminished antibacterial activity compared to the unconjugated peptoids (1a and 1b).
When comparing 6a to 1a, the nisin–peptoid conjugate is approximately five-fold less active than the
parent peptoid (i.e., MIC 5–10 µM compared to 2 µM) and this reduction in activity is similarly seen
when comparing peptoid 6b and 1b (MIC 9–18 µM vs. 2–4 µM). However, despite the reduction in
activity compared to the peptoids alone, the MIC values for 6a and 6b are still in the low micromolar
range against a drug resistant bacterium. In addition, 6a has a MIC similar to that of full-length
nisin (3), and one that is considerably better than truncated nisin[1–12] (4).
In order to ascertain whether the decreased activity displayed by the nisin–peptoid conjugates
(when compared to their parent peptoid sequences) was accompanied by a beneficial reduction
in toxicity, cytotoxicity assays were performed against HaCaT keratinocytes and epithelial HepG2
cells. Results for this testing can be found in the ESI and the data obtained shows that the peptoid
sequences with the N terminal alkyne (2a and 2b) were the most cytotoxic to both mammalian cell lines
tested (ED50 values of <20 µM). The nisin-conjugated peptoid sequences 6a and 6b were found to be
moderately cytotoxic to both mammalian cell lines tested (e.g., ED50 values of 22 µM and 24 µM against
HaCaT for 6a and 6b respectively). The ED50 values obtained also showed that the nisin–peptoid
hybrids (6a and 6b) have either a similar level or increased toxicity to the HaCaT cells compared
to the parent peptoids 1a and 1b (e.g., ED50 values of 26 µM and 53 µM against HaCaT for 1a and
1b respectively).
3. Materials and Methods
3.1. Linear Peptoid Synthesis (1a, 1b, 2a and 2b)
Fmoc-protected Rink Amide resin (0.1 mmol, loading 0.82 mmol g−1) was swollen in DMF (at
least 1 h, overnight preferred, at room temperature) in a 20 mL polypropylene syringe fitted with
two polyethylene frits. The resin was deprotected with piperidine (20% in DMF v/v, 2 × 20 min) and
washed with DMF (3 × 2 mL). The resin was treated with bromoacetic acid (1 mL, 0.6 M in DMF) and
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DIC (0.20 mL, 50% v/v in DMF) for 20 min at room temperature at 400 rpm. The resin was washed
with DMF (3 × 2 mL), before the desired amine sub-monomer was added (1 mL, 0.8–2.0 M in DMF)
and allowed to react for 60 min at room temperature on the shaker. The resin was again washed with
DMF (3 × 2 mL) and the bromoacetylation and amine displacement steps were repeated until the
final submonomer had been added and the desired peptoid sequence had been obtained. The resin
was shrunk in diethyl ether to remove DMF in preparation for cleavage. Final cleavage from resin
was achieved using TFA (95%), H2O (2.5%) and TIPS (2.5%). For test cleaves approximately 1 mL
of the cleavage cocktail was used and for cleavage from 100 mg resin, approximately 4 mL of the
cleavage cocktail was added. The resin was then placed on the shaker at 400 rpm for 45 min and
the resin removed by filtration. The cleavage cocktail was removed in vacuo, the crude product
precipitated in diethyl ether (45 mL) and the precipitate retrieved by centrifuge for 15 min at 5000
rpm. The ether phase was decanted, the crude product dissolved in a mixture of acidified H2O and
MeCN and lyophilized. Crude peptoid sequences were purified using RP-HPLC prior to ligation with
nisinA/B. For further details see the Supplementary Materials.
3.2. Amide-Coupled Azide-NisinA/B (5)
Nisin (600 mg, 0.18 mmol) was dissolved in 250 mL Tris buffer (25 mmol, NaOAc, 5 mmol Tris
acetate, 5 mmol CaCl2, pH 7.0) and the solution cooled on ice for 15 min. Trypsin (50 mg) was added
and stirred at room temperature for 15 min. The mixture was then heated to 30 ◦C for 16 h, then
another 50 mg of trypsin was added and after an additional 24 h the reaction was complete by HPLC.
The reaction was acidified with HCl (1 M) to pH 4.0 and solvents removed in vacuo. The nisin fragment
was isolated by preparative HPLC and product fractions lyophilized to obtain a white powder (80 mg,
39%). NisinA/B was dissolved in DMF (240 µL). BOP (2 eq.), DIPEA (4 eq.) and azidopropylamine
(50 eq.) were added. The reaction was stirred for 20 min then quenched in the appropriate buffer (95%
H2O, 5% MeCN, 0.1% TFA, 4 mL). The solution was centrifuged for 5 min at 5000 rpm to remove any
insoluble material and the supernatant was purified by RP-HPLC. Relevant fractions were collected
and analyzed to yield the pure NisinA/B-azide. For further details see the Supplementary Materials.
3.3. Click Protocol of Alkyne-Peptoids with NisinA/B-Azide (6a, 6b)
10× stock solutions of CuSO4 (16.2 µmol, 2.59 mg in 1 mL H2O), 10× sodium ascorbate (32.4 µmol,
6.42 mg in 1 mL H2O) and 10× TBTA (4.1 µmol, 2.18 mg in 1 mL DMF) were freshly prepared.
NisinA/B-azide (1 eq., 8.1 µmol, 10 mg) was dissolved in 200 µL DMF and added to the peptoid in
the microwave reaction vessel (1 eq., 8.1 µmol). 100 µL of the CuSO4 solution (0.2 eq., 1.62 µmol),
100 µL of sodium ascorbate stock (0.4 eq., 3.24 µmol) and 100 µL of the TBTA solution (0.05 eq.,
0.41 µmol) were added. The vessel was sealed and heated under microwave power for 20 min at
80 ◦C. The reaction mixture was diluted in the appropriate buffer (95% H2O, 5% MeCN, 0.1% TFA,
4 mL) and purified by RP-HPLC on a Reprospher 100 C8- or C18- Aqua column (10 µm × 250 mm×
20 mm) at a flow rate of 6 mL min−1; λ = 214 nm; linear gradient elution 20–80% solvent B over 120 min
(where A = 95% H2O, 5% MeCN, 0.1% TFA; B = 95% MeCN, 5% H2O, 0.1% TFA). Relevant fractions
were combined and lyophilized from 1:1 H2O:tBuOH mixture to yield purified peptoid–peptide
conjugates as a white powder.
3.4. MIC Determination
Compound stocks in DMSO were diluted 50× in cation-adjusted Mueller Hinton broth (CAMHB;
10 mg L−1 Mg2+, 50 mg L−1 Ca2+) and serially diluted in polypropylene 96-well plates to reach
a volume of 50 µL per well. MRSA USA300 was grown in TSB until the exponential growth phase
(OD600 = 0.5) before dilution in CAMHB and addition to the wells (50 µL) to reach a final CFU
concentration of 5 × 105 mL−1. After overnight incubation (35 ◦C, 250 RPM) the plates were inspected
visually for growth. Experiments were carried out in duplicate.
Molecules 2018, 23, 1566 7 of 9
4. Conclusions
In conclusion, an efficient and direct methodology that allows the semi-synthesis of novel
nisin–peptoid hybrids (6a and 6b) has been developed. The key step in the process involves the
use of a Cu(I) catalyzed click reaction. 6a and 6b were found to have low micromolar activity
against methicillin-resistant S. aureus (USA300) with MIC values of 5 µM and 9 µM respectively.
This antibacterial activity is similar to full-length nisin (3) (MIC 5 µM), and is considerably better
than truncated nisin[1–12] (4) MIC > 100 µM. Given the aforementioned results the primary aim of
the work to prepare semi-synthetic nisin analogues with comparable activity to full-length nisin has
been achieved. Building on from this proof of concept study we are now expanding the library of
nisin–peptoid hybrids, and, looking to investigate in more detail whether this class peptide–peptoid
hybrid displays a lipid II targeting mode of action.
Supplementary Materials: Full materials, synthesis and purification methods, biological protocols,
and characterization data for all compounds synthesized are available online.
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